ASCO 2026 | Tagraxofusp, hyper-CVAD, and venetoclax for patients with BPDCN: Phase II study results
Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses recent advances in blastic plasmacytoid dendritic cell neoplasm (BPDCN), focusing on the FDA-approved agent tagraxofusp (TAG). Dr Pemmaraju shares insights into a study evaluating the combination of TAG with hyper-CVAD and venetoclax, which appears to be safe and effective and may be used as a bridge to stem cell transplant. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s a very exciting time in our BPDCN field, blastic plasmacytoid dendritic cell neoplasm. We have not only one, but now two FDA approvals, and the first in class was that of Tagraxofusp, or TAG, a CD123 targeted agent that really was the first ever drug approved for BPDCN specifically, and that’s for ages two and older for both frontline & relapsed/refractory...
It’s a very exciting time in our BPDCN field, blastic plasmacytoid dendritic cell neoplasm. We have not only one, but now two FDA approvals, and the first in class was that of Tagraxofusp, or TAG, a CD123 targeted agent that really was the first ever drug approved for BPDCN specifically, and that’s for ages two and older for both frontline & relapsed/refractory. Now, the single agent data, my group and I have already put out there, New England Journal 2019, follow-up paper in JCO a few years ago with three-year follow-up. So as a monotherapy agent, that drug is approved and we have long-term follow-up. We asked the question, can we combine that agent, TAG, with other effective agents historically for BPDCN? And so we’re really proud to present those results here at ASCO, which looks at the combination of TAG, so CD123 targeted, with hyper-CVAD, cytotoxic chemotherapy that crosses the blood-brain barrier, and venetoclax. And essentially what we show here at the ASCO meeting is that this combination is not only safe and effective, but possibly can result in patients being bridged to stem cell transplant. Number two, perhaps a reduction in central nervous system CNS events. And number three, starting to see long-term survivors past five years. So it’s very exciting to see combinatorial data. We’ve seen that in our other fields, such as AML and ALL leukemias, and so we’re hoping to do the same for BPDCN.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
